[go: up one dir, main page]

MA37475A1 - Biomarqueurs pour thérapie par inhibiteur de iap - Google Patents

Biomarqueurs pour thérapie par inhibiteur de iap

Info

Publication number
MA37475A1
MA37475A1 MA37475A MA37475A MA37475A1 MA 37475 A1 MA37475 A1 MA 37475A1 MA 37475 A MA37475 A MA 37475A MA 37475 A MA37475 A MA 37475A MA 37475 A1 MA37475 A1 MA 37475A1
Authority
MA
Morocco
Prior art keywords
biomarkers
iap inhibitor
inhibitor therapy
iap
therapy
Prior art date
Application number
MA37475A
Other languages
English (en)
Inventor
John Scott Cameron
Caroline Emery
Dale Porter
Douglas Robinson
Kavitha Venkatesan
Li Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37475A1 publication Critical patent/MA37475A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de sélection d'un sujet ayant un cancer pour traitement avec un inhibiteur de iap.
MA37475A 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap MA37475A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642899P 2012-05-04 2012-05-04
PCT/US2013/039362 WO2013166344A1 (fr) 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap

Publications (1)

Publication Number Publication Date
MA37475A1 true MA37475A1 (fr) 2016-05-31

Family

ID=48407833

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37475A MA37475A1 (fr) 2012-05-04 2013-05-03 Biomarqueurs pour thérapie par inhibiteur de iap

Country Status (19)

Country Link
US (1) US9353419B2 (fr)
EP (1) EP2844764B1 (fr)
JP (1) JP6513019B2 (fr)
KR (1) KR20150011822A (fr)
CN (1) CN104284988A (fr)
AU (1) AU2013256182A1 (fr)
BR (1) BR112014027413A2 (fr)
CA (1) CA2871995A1 (fr)
CL (1) CL2014002976A1 (fr)
ES (1) ES2593046T3 (fr)
IL (1) IL235315A0 (fr)
MA (1) MA37475A1 (fr)
MX (1) MX2014013429A (fr)
PH (1) PH12014502461A1 (fr)
RU (1) RU2014148779A (fr)
SG (1) SG11201406837TA (fr)
TN (1) TN2014000443A1 (fr)
TW (1) TW201347760A (fr)
WO (1) WO2013166344A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974651A1 (fr) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Polytherapie anticancereuse a base de smc
EP3229807A4 (fr) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibiteurs de nécrose cellulaire et procédés associés
CA3080943A1 (fr) * 2017-11-01 2019-05-09 The Regents Of The University Of California Nouveaux agents ciblant des proteines inhibitrices de l'apoptose
AU2018364218B2 (en) 2017-11-13 2023-03-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SMAC mimetics used as IAP inhibitors and use thereof
WO2025187844A1 (fr) * 2024-03-06 2025-09-12 Taiho Pharmaceutical Co., Ltd. Biomarqueurs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
AU2003265276A1 (en) 2002-07-15 2004-02-02 The Trustees Of Princeton University Iap binding compounds
WO2005069894A2 (fr) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Mimetiques de smac contraints de maniere conformationnelle et utilisations associees
CN1933847A (zh) 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
EP1740173A4 (fr) 2004-03-23 2009-05-27 Genentech Inc Inhibiteurs azabicyclo-octane de l'iap
SG152225A1 (en) 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
RS53734B1 (sr) 2004-07-02 2015-06-30 Genentech Inc. Inhibitori iap
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
WO2007072225A2 (fr) * 2005-12-01 2007-06-28 Medical Prognosis Institute Méthodes et appareils pour identifier des biomarqueurs de réponse à un traitement et leur utilisation pour prédire l'efficacité d’un traitement
CN101529254A (zh) * 2006-10-19 2009-09-09 诺瓦提斯公司 有机化合物
BRPI0717411A2 (pt) 2006-10-19 2013-11-12 Novartis Ag Uso de inibidores de iap
RU2491276C2 (ru) 2007-04-30 2013-08-27 Дженентек, Инк. Ингибиторы iap
US20120015352A1 (en) 2009-01-29 2012-01-19 Otto-Von-Guericke-Universitat Magdeburg Method of determining sensitivity of human or non-human animal cells to an iap antagonist
DK3301446T3 (da) * 2009-02-11 2020-06-29 Caris Mpi Inc Molekylær tumorprofilering
EP2478358A1 (fr) 2009-09-18 2012-07-25 Novartis AG Biomarqueurs associés aux composés inhibiteurs des iap
CN101956014B (zh) 2010-09-30 2014-05-28 中山大学 一种用于鼻咽癌早期诊断的外周血7个基因标志物的检测试剂盒

Also Published As

Publication number Publication date
RU2014148779A (ru) 2016-06-27
US20150105434A1 (en) 2015-04-16
EP2844764B1 (fr) 2016-06-22
IL235315A0 (en) 2014-12-31
TN2014000443A1 (en) 2016-03-30
BR112014027413A2 (pt) 2017-06-27
WO2013166344A1 (fr) 2013-11-07
ES2593046T3 (es) 2016-12-05
CA2871995A1 (fr) 2013-11-07
EP2844764A1 (fr) 2015-03-11
CL2014002976A1 (es) 2015-02-13
US9353419B2 (en) 2016-05-31
SG11201406837TA (en) 2014-11-27
CN104284988A (zh) 2015-01-14
PH12014502461A1 (en) 2014-12-22
JP2015523056A (ja) 2015-08-13
AU2013256182A1 (en) 2014-11-13
MX2014013429A (es) 2014-12-08
JP6513019B2 (ja) 2019-05-15
HK1202589A1 (zh) 2015-10-02
TW201347760A (zh) 2013-12-01
KR20150011822A (ko) 2015-02-02

Similar Documents

Publication Publication Date Title
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
BR112013024211A2 (pt) tratamento de tumores sólidos
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
MX2014011500A (es) Diagnosticos y tratamientos relacionados a inhibidores her3.
MX2015012644A (es) Tratamiento de cataplejia.
EA201400178A1 (ru) Лечение рака молочной железы
EP2763988A4 (fr) Composés pyrrolopyrimidines pour le traitement du cancer
UA110813C2 (uk) Лікування ліподистрофії
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
EP3486657A3 (fr) Dispositif et methodes pour le diagnostic du cancer du pancréas
BR112013025755A2 (pt) aparelho de guincho
MA47408B1 (fr) Traitement du cancer
BR112013027726A2 (pt) instalação de poço submarino e método associado
HUS2000037I1 (hu) Triazinok Protozoa okozta betegségek kezelésére
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
EA201492104A1 (ru) Ингибитор jak1/2
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
GB2510539A (en) Biomarkers of cancer
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
BR112013029439A2 (pt) válvula de alívio
EP2812338A4 (fr) Méthode de traitement d'un cancer nasopharyngé
IN2014DN07162A (fr)